– Positive Phase 2 study results demonstrate significant efficacy of donidalorsen (formerly IONIS-PKK-LRx) in the reduction of hereditary angioedema attacks – Based on the results of the Phase 2 study, Ionis plans to initiate a Phase 3 program of donidalorsen in people with HAE CARLSBAD, Calif.
Ionis reports third quarter 2021 financial results and recent business achievements
Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
– More than 3 million people in the US have severe hypertriglyceridemia – The CORE Phase 3 clinical study further expands Ionis’ late-stage pipeline and is the second Phase 3 clinical study in Ionis’ broad olezarsen development program – Olezarsen is one of Ionis’ wholly owned medicines the company
Ionis to hold third quarter 2021 financial results webcast
Webcast scheduled for Wednesday, November 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Oct. 20, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m.
Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
– In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed –